LJPC stock performance?

La Jolla Pharmaceutical Company (LJPC) news stock charts

La Jolla Pharmaceutical Company (LJPC) Investment Summary:

La Jolla Pharmaceutical Company was incorporated in Delaware in 1989. In October 2004 the Company established a subsidiary, La Jolla Limited, which was organized in England in connection with the potential development efforts for Riquent in Europe. We are a biopharmaceutical company focused on the research and development of highly specific therapeutic products for the treatment of certain life-threatening antibody-mediated diseases. These diseases, including autoimmune conditions such as lupus, are caused by abnormal B cell production of antibodies that attack healthy tissues. Current treatments for these autoimmune disorders often address only symptoms of the disease, or nonspecifically suppress the normal operation of the immune system, which can result in severe, negative side effects and hospitalization.  ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2005%2f03%2f10%2f0000950137-05-002829.html#FIS_BUSINESS"   
www.ljpc.com
94 Employees
Founded in 1989

LA JOLLA PHARMACEUTICAL CO (LJPC:Pink OTC Markets Inc)

LAST $0.08 USD
CHANGE TODAY -0.0101 -11.87%
VOLUME 3.6M
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).

Snapshot of LA JOLLA PHARMACEUTICAL CO (LJPC)

OPEN
$0.09
PREVIOUS CLOSE
$0.09
DAY HIGH
$0.09
DAY LOW
$0.07
52 WEEK HIGH
05/8/09 - $0.64
52 WEEK LOW
11/19/09 - $0.06
MARKET CAP
4.9M
AVERAGE VOLUME 10 D
1.4M
EPS TTM
$-0.38
SHARES OUTSTANDING
65.7M
LJPC Does Not Pay Dividends
P/E TTM
--
K = Thousands  M = Millions  B = Billions

related news

Benlysta Effective in Some Lupus Sufferers
Benlysta Effective in Some Lupus Sufferers

Key developments for LA JOLLA PHARMACEUTICAL CO (LJPC)

La Jolla Pharmaceutical Announces Delisting From NASDAQ

La Jolla Pharmaceutical Company announced that it received notification from the NASDAQ Hearings Panel that the Panel has determined to deny the Companys request for continued listing on The NASDAQ Stock Market and that trading of the Company's common stock will be suspended effective at the open of business on March 4, 2010. The Panel determined that the Company is operating as a public shell because of the Companys nominal assets, other than cash, and the Companys nominal operations. The Company also announced that holders of only thirteen percent (13%) of La Jollas outstanding common stock returned their proxy cards or otherwise indicated their votes with respect to proposals related to its proposed merger with Adamis Pharmaceuticals Corporation, prior to the start of the stockholders meeting. As a result, there was no quorum to conduct the meeting. The meeting and the solicitation of further votes has been canceled due to the delisting from NASDAQ. The Company anticipates that its common stock will be quoted on the Pink OTC Markets Inc. automatically and immediately after NASDAQ suspends trading, provided that a market maker, who has quoted the Companys common stock in the 30 days prior to delisting, enters a quote on the Pink Sheets prior to market close on March 4, 2010. The Company's common stock may, in the future, also be quoted on the Over-the-Counter Bulletin Board. A Form 25-NSE will be filed with the Securities and Exchange Commission to remove the Companys securities from listing and registration on NASDAQ.

La Jolla Pharmaceutical Co., Special/Extraordinary Shareholders Meeting, Mar 02, 2010

La Jolla Pharmaceutical Co., Special/Extraordinary Shareholders Meeting, Mar 02, 2010, at 15:00 US Pacific Time. Agenda: To propose merger with Adamis Pharmaceuticals Corporation .

La Jolla Receives Letter From NASDAQ

On January 19, 2010, La Jolla Pharmaceutical Co. received a notice (the Notice) from the NASDAQ Stock Market indicating that NASDAQ believes that the Company is operating as a public shell and that the resulting entity in the proposed merger between the Company and Adamis Pharmaceuticals Corporation (Adamis) will not meet NASDAQs initial listing requirements. NASDAQ has determined that public shells could be detrimental to the interests of the investing public. Listing Rule 5101 provides NASDAQ with discretionary authority to apply more stringent criteria for continued listing and terminate the inclusion of particular securities based on any event that occurs that in the opinion of NASDAQ makes inclusion of the securities on NASDAQ inadvisable or unwarranted. The Company intends to appeal the determination in the January 19 letter. Absent such an appeal, trading of the Companys common stock would be suspended at the open of business on January 28, 2010 and a Form 25-NSE would be filed with the Securities and Exchange Commission to remove the Companys securities from listing and registration on NASDAQ. The Companys appeal will stay the suspension of the trading of the Companys common stock pending a final decision by a NASDAQ Listing Qualifications Panel. The Company must submit its request for a hearing no later than January 26, 2010. Notwithstanding the appeal, the Company expects that its stock will be delisted following the completion of the merger with Adamis as the transaction will constitute a change of control and the combined entity is not expected to satisfy the NASDAQ initial listing standards that would be applied at that time.

La Jolla Pharmaceutical Company financial resources

otc, otcbb, pinksheet, LJPC, ob La Jolla Pharmaceutical Company

LJPC Competitors

Company Last Change
No competitor information is available for LJPC.
Market data is delayed at least 15 minutes.
 

Industry Analysis

Valuation LJPC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.7x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

LJPC

 | 

LJPC transactions

Type
Date
Target
Merger/Acquisition
October 16, 2009
--

More Recent Financial News About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company Provides Voting Update - More Votes Needed or La Jolla Will Likely Close

Quote:
Read article

La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders

Quote:
Read article

La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders

Quote:
Read article

LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Quote: LA JOLLA PHARMACEUTICAL CORequest a Trial to NEW EDGAR Online Pro Form 8-K for LA JOLLA PHARMACEUTICAL CO 1-Mar-2010Other Events, Financial Statements and Exhibits Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any inf...
Read article

LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Quote: LA JOLLA PHARMACEUTICAL CORequest a Trial to NEW EDGAR Online Pro Form 8-K for LA JOLLA PHARMACEUTICAL CO 24-Feb-2010Other Events, Financial Statements and Exhibits Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any in...
Read article

La Jolla Pharmaceutical Company Provides Voting Update - More Votes Needed or La Jolla Will Likely Close

Quote:
Read article

LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Quote: LA JOLLA PHARMACEUTICAL CORequest a Trial to NEW EDGAR Online Pro Form 8-K for LA JOLLA PHARMACEUTICAL CO 19-Feb-2010Other Events, Financial Statements and Exhibits Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any in...
Read article

LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Quote: LA JOLLA PHARMACEUTICAL CORequest a Trial to NEW EDGAR Online Pro Form 8-K for LA JOLLA PHARMACEUTICAL CO 16-Feb-2010Other Events, Financial Statements and Exhibits Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any in...
Read article

La Jolla Pharmaceutical Company Receives Nasdaq Delisting Notice and Intends to Appeal Determination

Quote:
Read article

Emerging Stock Report Initiates Independent Research Coverage on La Jolla Pharmaceutical Company (LJPC)

Quote: 8, 2009 (GLOBE NEWSWIRE) -- Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on La Jolla Pharmaceutical Company (Nasdaq: -To view the Report in its entirety visit:To get our alerts AHEAD of the market follow us on Twitter:Emerging Stock Report is a leading provider of independent investment research for North American companies. Our services include research analysis on emerging growth companies, sector specific research, real...
Read article

Stock Watch: InvestorSoup.com issues Market Alert for La Jolla Pharmaceuticals Co.

Quote: The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision. http://www.investorsoup.com/lp/LJPC www.twitter.com/investorsoup La Jolla Pharmaceutical Co. (LJPC) is a biopharmaceutical company focused on the development and testing of Riquent as a treatment for lupus nephritis, an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. The Company'...
Read article

La Jolla Pharmaceutical Company Announces Filing of Joint Proxy Statement/Prospectus

Quote:
Read article

LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or

Quote: Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 19, 2010, La Jolla Pharmaceutical Company (the "Company") received a notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") indicating that Nasdaq believes that the Company is operating as a "public shell" and that the resulting entity in the proposed merger between the Company and Adamis Pharmaceuticals Corporation ("...
Read article

La Jolla Pharmaceutical Company Receives Nasdaq Delisting Notice and Intends to Appeal Determination

Quote:
Read article

Biotech Stock Alert for La Jolla Pharmaceutical Co. Issued by StockPreacher

Quote: The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.http://www.stockpreacher.com/n/LJPChttp://twitter.com/StockPreacherLa Jolla Pharmaceutical Co. (LJPC) is a biopharmaceutical company focused on the development and testing of Riquent as a treatment for Lupus nephritis. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissue...
Read article

Biotech Stock Alert for La Jolla Pharmaceutical Co. Issued by StockPreacher

Quote: The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.http://www.stockpreacher.com/n/LJPChttp://twitter.com/StockPreacherLa Jolla Pharmaceutical Co. (LJPC) is a biopharmaceutical company focused on the development and testing of Riquent as a treatment for Lupus nephritis. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissue...
Read article

La Jolla Pharmaceutical Company Announces Filing of Joint Proxy Statement/Prospectus

Quote:
Read article

LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events

Quote: Item 8.01 Other Events. On December 22, 2009, La Jolla Pharmaceutical Company ("La Jolla") announced that it has filed its Registration Statement on Form S-4 with the Securities and Exchange Commission in connection with its proposed merger with Adamis Pharmaceuticals Corporation ("Adamis"). The definitive merger agreement was entered into on December 4, 2009 and closing of the merger is subject to certain closing conditions, including approval by the stockholders of La Joll...
Read article

Stock Watch: InvestorSoup.com Issues Market Alert for La Jolla Pharmaceuticals Co.

Quote: The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision. http://www.investorsoup.com/lp/LJPC www.twitter.com/investorsoup La Jolla Pharmaceutical Co. (LJPC) is a biopharmaceutical company focused on the development and testing of Riquent as a treatment for lupus nephritis, an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. The Company'...
Read article

LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pri

Quote:
Read article

Would you like to leave a comment about La Jolla Pharmaceutical Company LJPC

Besides La Jolla Pharmaceutical Company's Stock there is more great penny stock and market information at Realpennies